BNTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
BioNTech SE
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 10, 2026
$89.21+1.50 (+1.71%)
Close on Oct 19, 2026
Share price
−$15.93 (−15.15%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
BioNTech SE grew revenue 4.3% to €2.87B over fiscal 2025. Free cash flow was €280.90M.
Revenue
€2.87B
+4.3% vs. a year earlier
Operating income
-€1.40B
FY2025
Free cash flow
€280.90M
FY2025
EPS, diluted
-4.70 EUR
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- €2.87B
- Net income
- -€1.14B
- EPS, diluted
- -4.70 EUR
- Free cash flow
- €280.90M
Valuation needs the share price. It fills in once daily prices are connected and converted from EUR.
Ten years at a glance
Fiscal years 2016 to 2025, EUR
Revenue
€2.87B+4.3% YoY
Gross profit
€2.23B+0.8% YoY
Operating income
-€1.40B
Net income
-€1.14B
EPS, diluted
-4.70 EUR
Free cash flow
€280.90M
Reported period